Videos and Podcasts

30th Jun 21

Pharmaxis Encouraged by First Results in Bone Marrow Cancer Trial

Pharmaxis CEO Gary Phillips speaks to Proactive Investors about the myelofibrosis clinical trial which is being conducted with patients in Australia and South Korea and the potential for other cancer indications.

Watch the interview here.  

4th Jun 21

Virtual Investor Briefing - 4 June 2021

Watch a recording of the Pharmaxis virtual investor briefing by the chief executive officer Mr Gary Phillips on Friday 4 June 2021.

Watch recording here.

4th May 21

Pharmaxis drug to be focus of new brain cancer study with grant from Charlie Teo Foundation

Pharmaxis Ltd's (ASX:PXS) (FRA:UUD) CEO Gary Phillips tells Proactive's Andrew Scott its drug PXS-5505 will be the focus of a new study, funded by a grant from the Charlie Teo Foundation, looking at an aggressive and deadly form of brain cancer. The drug, which has commenced a phase 1/2a clinical trial for the rare bone marrow cancer myelofibrosis, will now enter pre-clinical efficacy testing for glioblastoma (GBM), the most common form of brain cancer with an average survival of only 15 months from diagnosis.

Watch the interview here.